Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.66 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.57 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10535992 | 0.91 | GP6 (0.59) | GP6AGTR1AGTR2PPARG | |
| SCHEMBL17949543 | 0.90 | PPARG (0.57) | GP6AGTR1AGTR2PPARG | |
| SCHEMBL21083688 | 0.90 | GP6 (0.59) | GP6AGTR1AGTR2PPARG | |
| SCHEMBL21083964 | 0.89 | GP6 (0.56) | GP6AGTR1AGTR2PPARG | |
| SCHEMBL3459616 | 0.88 | PPARG (0.59) | GP6AGTR1AGTR2PPARG | |
| SCHEMBL21083785 | 0.87 | GP6 (0.55) | GP6AGTR1AGTR2PPARG | |
| SCHEMBL21083673 | 0.87 | GP6 (0.55) | GP6AGTR1AGTR2 | |
| SCHEMBL13278168 | 0.86 | PPARG (0.53) | GP6AGTR1AGTR2PPARG | |
| SCHEMBL12716740 | 0.86 | PPARG (0.61) | AGTR1AGTR2PPARG | |
| SCHEMBL6430 | 0.86 | PPARG (0.61) | AGTR1AGTR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023181045-A1 | PROCESS FOR THE PREPARATION OF CARCINOGENIC AZIDO IMPURITIES FREE LOSARTAN AND SALTS THEREOF | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-09-28 | — | — | WO | disclosed |
| WO-2021036193-A1 | PREPARATION METHOD FOR LOSARTAN | 浙江天宇药业股份有限公司 | 2021-03-04 | — | — | WO | disclosed |
| US-9604974-B2 | Compounds as modulator of JAK-STAT pathway, methods and applications thereof | UNIVERSITY OF MYSORE (IN) | 2017-03-28 | — | — | US | disclosed |
| US-9604974-B2 | Compounds as modulator of JAK-STAT pathway, methods and applications thereof | UNIVERSITY OF MYSORE (IN) | 2017-03-28 | — | — | US | disclosed |
| US-20160214968-A1 | COMPOUNDS AS MODULATOR OF JAK-STAT PATHWAY, METHODS AND APPLICATIONS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-07-28 | — | — | US | disclosed |
| US-20160214968-A1 | COMPOUNDS AS MODULATOR OF JAK-STAT PATHWAY, METHODS AND APPLICATIONS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-07-28 | — | — | US | disclosed |
| US-8569528-B2 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-8569528-B2 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-20120330026-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | NOVARTIS AG (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20120330026-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | NOVARTIS AG (CH) | 2012-12-27 | — | — | US | disclosed |
| EP-0324377-B1 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | DU PONT (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5599943-A | Method for producing tetrazolylbenzene compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-02-04 | — | — | US | disclosed |
| EP-0733366-A2 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5484955-A | Tri-higher alkyl tin azide and its use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-16 | — | — | US | disclosed |
| EP-0578125-A1 | Tri-higher alkyl tin azide and its use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-01-12 | — | — | EP | disclosed |
| US-5155118-A | Administering angiotensin inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120330026-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | ABL1, TBCA, TBC1D5 | GP6 1337/4885AGTR1 2005/4885AGTR2 1882/4885 |
| US-20160214968-A1 | COMPOUNDS AS MODULATOR OF JAK-STAT PATHWAY, METHODS AND APPLICATIONS THEREOF | STAT3, STAT1, JAK2 | GP6 927/4885AGTR1 3590/4885AGTR2 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.